Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HERTHENA-PanTumor01 (U31402-277)
CTR20254724Phase 2Active
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Feb 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of patritumab deruxtecan in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, non-small cell lung cancer (NSCLC), breast cancer, prostate cancer (PCa), sponsored by Daiichi Sankyo Co., Ltd.. Started Feb 2026; status: active.
02
Drugs
patritumab deruxtecan
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinomanon-small cell lung cancer (NSCLC)breast cancerprostate cancer (PCa)
Beyond the preview
Go deeper on CTR20254724.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254724.